Licoricidin

Research use only, not for human use.

Licoricidin, is a potent anti-metastatic agent, which can markedly inhibit the metastatic and invasive capacity of malignant prostate cancer cells.

Licoricidin, is a potent anti-metastatic agent, which can markedly inhibit the metastatic and invasive capacity of malignant prostate cancer cells.

Licoricidin (LCD) (0-20 μM; 24 hours) dose-dependently inhibits the viability of colon cancer cell lines with various pathological and genetic characters, namely SW480, HCT116, SW620 and LoVo cells, with IC50 values of 7.2, 5.4, 4.5 and 5.1 μM, respectively.Licoricidin (LCD) (0-20 μM; 0-12 hours) induces cell apoptosis was accompanied with the activation of caspase-3 by cleavage in a time- and dose-dependent manner.Licoricidin (LCD) (0-20 μM; 0-12 hours) induces autophagy of SW480 cells, increases the cleavage of LC3-I to LC3-II and the degradation of p62 in a time and dose dependent manner.Licoricidin (LCD) (0-5 μg/ml; 18 hours) inhibits cell migration, MMP-9 secretion, and VCAM expression in 4T1 cells.Cell Viability Assay Cell Line:SW480, HCT116, SW620 and LoVo cells Concentration:0-20 μM Incubation Time:24 hours Result:Decreased colon cancer cell lines viability.Western Blot Analysis Cell Line:SW480 cells Concentration:0 μM, 2.5 μM, 5 μM, 10 μM, 20 μM Incubation Time:0 hours, 1 hour, 3 hours, 6 hours, 12 hours Result:Induced cell apoptosis.

Licoricidin (LCD) (intraperitoneal injection; 5, 10, or 20 mg/kg; once daily; 15 days) significantly inhibited the growth of SW480 xenografts in nude mice with an inhibitory rate of 43.5%.Licoricidin (LCD) (intraperitoneal injection; 5, 10, or 20 mg/kg; once daily; 32 days) reduces pulmonary metastasis and the expression of CD45, CD31, HIF-1α, iNOS, COX-2, and VEGF-A in tumor tissues, additionally, decreases protein expression of VEGF-R2, VEGF-C, VEGF-R3, and LYVE-1 in tumor tissues of licoricidin-treated mice. Animal Model:SW480 xenografted tumor growth in nude mice Dosage: 5, 10, or 20 mg/kg Administration:Intraperitoneal injection; once daily; 15 days Result:Decreased tumor volumes.Animal Model:BALB/c mouse orthotopic model Dosage:5, 10, or 20 mg/kg Administration:Intraperitoneal injection; 5, 10, or 20 mg/kg; once daily; 32 days Result:Inhibited Lung Metastasis of 4T1 Murine Mammary Carcinoma cells.

——

Others

Other Targets

——

——

——

30508-27-1

424.5

C26H32O5

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (235.55 mM)

——

——

(-20℃)

With Ice Pack

≥ 2 years